Savolitinib (Orpathys®) is an orally bioavailable and highly selective small molecule MET–TKI that has demonstrated profound efficacy in preclinical and clinical studies of various cancers, including NSCLC, papillary renal cell carcinoma (PRCC) and gastric carcinoma [32,33,34]. This evidence concerns the gene MET and cancer.